We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+29.88%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.78B
AUM Growth
+$40.3M
Cap. Flow
-$635M
Cap. Flow %
-22.8%
Top 10 Hldgs %
41.28%
Holding
156
New
21
Increased
23
Reduced
32
Closed
45

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$77.3M
2
ACHN
Achillion Pharmaceuticals
ACHN
+$35.7M
3
NVRO
NEVRO CORP.
NVRO
+$33M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$23.3M
5
AGN
Allergan Inc
AGN
+$22.9M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$46M
2
ABBV icon
AbbVie
ABBV
+$44.3M
3
KITE
Kite Pharma, Inc.
KITE
+$36M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$30.9M
5
WBA
Walgreens Boots Alliance
WBA
+$28.6M

Sector Composition

Rank Sector Weight
1 Healthcare 52.44%
2 Financials 2.69%
3 Technology 0.73%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRGE
76
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$3.18M 0.11%
892,897
-1,044,799
-54% -$3.09M
OCRX
77
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.94M 0.11%
461,119
– –
ANTH
78
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.67M 0.1%
211,482
– –
KIN
79
DELISTED
Kindred Biosciences, Inc.
KIN
$2.63M 0.09%
352,384
-57,479
-14% -$488K
IMMU
80
CALL
DELISTED
Immunomedics Inc
IMMU
$2.4M 0.09%
+500,000
New +$1.98M
ADPT
81
DELISTED
Adeptus Health Inc
ADPT
$2.36M 0.08%
63,053
-98,070
-61% -$3.09M
DERM
82
DELISTED
Dermira, Inc.
DERM
$2.11M 0.08%
+116,267
New +$1.94M
FLXN
83
DELISTED
Flexion Therapeutics, Inc.
FLXN
$2.02M 0.07%
+99,847
New +$1.81M
PARN
84
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$1.56M 0.06%
375,700
-6,945
-2% -$31.6K
PTN
85
Palatin Technologies
PTN
$16.2M
$1.46M 0.05%
1,600
– –
EXEL icon
86
CALL
Exelixis
EXEL
$14.1B
$1.44M 0.05%
1,000,000
– –
SLXP
87
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$1.32M 0.05%
11,500
+5,650
+97% +$684K
ABEO icon
88
Abeona Therapeutics
ABEO
$399M
$1.28M 0.05%
+14,895
New +$1.34M
EW icon
89
Edwards Lifesciences
EW
$49.4B
$1.27M 0.05%
+60,000
New +$1.21M
ZTS icon
90
Zoetis
ZTS
$32.1B
$1.08M 0.04%
+25,097
New +$1.02M
CASC
91
DELISTED
Cascadian Therapeutics, Inc.
CASC
$757K 0.03%
66,417
-309,022
-82% -$3.35M
ILMN icon
92
Illumina
ILMN
$28.2B
$738K 0.03%
+4,112
New +$725K
KND
93
DELISTED
Kindred Healthcare
KND
$684K 0.02%
37,611
-55,489
-60% -$1.1M
AGRX
94
DELISTED
Agile Therapeutics
AGRX
$645K 0.02%
53
– –
SVRA icon
95
Savara
SVRA
$1.13B
$392K 0.01%
+10,000
New +$349K
IMRS
96
DELISTED
IMRIS INC COMMON SHARES (CANADA)
IMRS
$124K ﹤0.01%
147,076
– –
ABBV icon
97
AbbVie
ABBV
$450B
– –
-766,400
Closed -$44.3M
ALKS icon
98
Alkermes
ALKS
$8.79B
– –
-55,000
Closed -$2.36M
ANGO icon
99
AngioDynamics
ANGO
$558M
– –
-682,740
Closed -$9.37M
ANIP icon
100
ANI Pharmaceuticals
ANIP
$1.8B
– –
-607,355
Closed -$17.2M
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2014 Portfolio in Review

As of Q4 2014, Deerfield Management held 156 positions worth $2.78B, up 1.5% from $2.74B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deerfield Management withdrew a net $635M in Q4 2014, closing 45 positions and reducing 32 holdings. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Achillion Pharmaceuticals worth $35.8M.

  • Deerfield Management's largest Q4 2014 buy was Achillion Pharmaceuticals: 2,920,300 shares worth $35.8M.
  • Deerfield Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014, an estimated $77.3M increase.
  • Deerfield Management's biggest Q4 2014 reduction was Kite Pharma, Inc., cutting an estimated $36M.
  • Deerfield Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2014, selling an estimated $46M.
  • Deerfield Management's ten largest holdings make up 41% of its $2.78B portfolio in Q4 2014.
  • Deerfield Management opened 21 new positions and closed 45 in Q4 2014.
  • Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.78B.

Based on Deerfield Management's 13F filing for Q4 2014, filed 17 Feb 2015.